LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Clinical trials for LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…
Matched conditions: LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New drug combo aims to shrink lung tumors better
Disease control Recruiting nowThis study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…
Matched conditions: LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC